Global Biosimilars Market Size study, By Product (Monoclonal Antibodies, Insulin, Granulocyte Colony-Stimulating Factor, Erythropoietin, Recombinant Human Growth Hormone, Etanercept, Follitropin, Teriparatide, Interferons, Enoxaparin Sodium, Glucagon, Calcitonin), By Indication (Oncology, Inflammatory & Autoimmune Disorders, Chronic Diseases, Blood Disorders, Growth Hormone Deficiency, Infectious Diseases, Other Indications), and Regional Forecasts 2022-2028
- BIZ4952957
- 200 Pages
- April 2022
- Pharmaceuticals
The key regions considered for the global Biosimilars market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. Europe is the leading region across the world in terms of market share owing to the growing incidence of chronic disorders and the introduction of new biosimilars. Whereas, Asia-Pacific is also anticipated to exhibit the highest CAGR over the forecast period 2022-2028. Factors such as the increasing population, as well as the emergence of new players and early entry into the market, would create lucrative growth prospects for the Biosimilars market across the Asia-Pacific region.
Major market players included in this report are:
Samsung Biologics
Intas Pharmaceuticals Ltd.
Celltrion
Reliance Life Sciences
Pfizer, Inc.
Coherus BioSciences
Dr. Reddy’s Laboratories Ltd.
Amgen, Inc.
Biocon Limited
Apotex, Inc.
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Product
Monoclonal Antibodies
Insulin
Granulocyte Colony-Stimulating Factor
Erythropoietin
Recombinant Human Growth Hormone
Etanercept
Follitropin
Teriparatide
Interferons
Enoxaparin Sodium
Glucagon
Calcitonin
By Indication
Oncology
Inflammatory & Autoimmune Disorders
Chronic Diseases
Blood Disorders
Growth Hormone Deficiency
Infectious Diseases
Other Indications
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World
Furthermore, years considered for the study are as follows:
Historical year – 2018, 2019,2020
Base year – 2021
Forecast period – 2022 to 2028
Target Audience of the Global Biosimilars Market in Market Study:
Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2020-2028(USD Billion)
1.2.1. Biosimilars Market, by Region, 2020-2028(USD Billion)
1.2.2. Biosimilars Market, by Product, 2020-2028(USD Billion)
1.2.3. Biosimilars Market, by Indication, 2020-2028(USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global Biosimilars Market Definition and Scope
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global Biosimilars Market Dynamics
3.1. Biosimilars Market Impact Analysis (2020-2028)
3.1.1. Market Drivers
3.1.1.1. Increasing geriatric population and the growing incidence of chronic diseases
3.1.1.2. Increasing demand for biosimilar drugs
3.1.2. Market Challenges
3.1.2.1. Complexities in manufacturing
3.1.3. Market Opportunities
3.1.3.1. Increasing investment for the introduction of new indications
Chapter 4. Global Biosimilars Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model (2019-2028)
4.2. PEST Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.3. Investment Adoption Model
4.4. Analyst Recommendation & Conclusion
4.5. Top investment opportunity
4.6. Top winning strategies
Chapter 5. Risk Assessment: COVID-19 Impact
5.1.1. Assessment of the overall impact of COVID-19 on the industry
5.1.2. Pre COVID-19 and post COVID-19 market scenario
Chapter 6. Global Biosimilars Market, by Product
6.1. Market Snapshot
6.2. Global Biosimilars Market by Product, Performance - Potential Analysis
6.3. Global Biosimilars Market Estimates & Forecasts by Product, 2019-2028 (USD Billion)
6.4. Biosimilars Market, Sub Segment Analysis
6.4.1. Monoclonal Antibodies
6.4.2. Insulin
6.4.3. Granulocyte Colony-Stimulating Factor
6.4.4. Erythropoietin
6.4.5. Recombinant Human Growth Hormone
6.4.6. Etanercept
6.4.7. Follitropin
6.4.8. Teriparatide
6.4.9. Interferons
6.4.10. Enoxaparin Sodium
6.4.11. Glucagon
6.4.12. Calcitonin
Chapter 7. Global Biosimilars Market, by Indication
7.1. Market Snapshot
7.2. Global Biosimilars Market by Indication, Performance – Potential Analysis
7.3. Global Biosimilars Market Estimates & Forecasts by Indication, 2019-2028 (USD Billion)
7.4. Biosimilars Market, Sub Segment Analysis
7.4.1. Oncology
7.4.2. Inflammatory & Autoimmune Disorders
7.4.3. Chronic Diseases
7.4.4. Blood Disorders
7.4.5. Growth Hormone Deficiency
7.4.6. Infectious Diseases
7.4.7. Other Indications
Chapter 8. Global Biosimilars Market, Regional Analysis
8.1. Biosimilars Market, Regional Market Snapshot
8.2. North America Biosimilars Market
8.2.1. U.S. Biosimilars Market
8.2.1.1. Product breakdown estimates & forecasts, 2019-2028
8.2.1.2. Indication breakdown estimates & forecasts, 2019-2028
8.2.2. Canada Biosimilars Market
8.3. Europe Biosimilars Market Snapshot
8.3.1. U.K. Biosimilars Market
8.3.2. Germany Biosimilars Market
8.3.3. France Biosimilars Market
8.3.4. Spain Biosimilars Market
8.3.5. Italy Biosimilars Market
8.3.6. Rest of Europe Biosimilars Market
8.4. Asia-Pacific Biosimilars Market Snapshot
8.4.1. China Biosimilars Market
8.4.2. India Biosimilars Market
8.4.3. Japan Biosimilars Market
8.4.4. Australia Biosimilars Market
8.4.5. South Korea Biosimilars Market
8.4.6. Rest of Asia Pacific Biosimilars Market
8.5. Latin America Biosimilars Market Snapshot
8.5.1. Brazil Biosimilars Market
8.5.2. Mexico Biosimilars Market
8.6. Rest of The World Biosimilars Market
Chapter 9. Competitive Intelligence
9.1. Top Market Strategies
9.2. Company Profiles
9.2.1. Samsung Biologics
9.2.1.1. Key Information
9.2.1.2. Overview
9.2.1.3. Financial (Subject to Data Availability)
9.2.1.4. Product Summary
9.2.1.5. Recent Developments
9.2.2. Intas Pharmaceuticals Ltd.
9.2.3. Celltrion
9.2.4. Reliance Life Sciences
9.2.5. Pfizer, Inc.
9.2.6. Coherus BioSciences
9.2.7. Dr. Reddy’s Laboratories Ltd.
9.2.8. Amgen, Inc.
9.2.9. Biocon Limited
9.2.10. Apotex, Inc.
Chapter 10. Research Process
10.1. Research Process
10.1.1. Data Mining
10.1.2. Analysis
10.1.3. Market Estimation
10.1.4. Validation
10.1.5. Publishing
10.2. Research Attributes
10.3. Research Assumption
TABLE 1. Global Biosimilars market, report scope
TABLE 2. Global Biosimilars market estimates & forecasts by Region 2019-2028 (USD Billion)
TABLE 3. Global Biosimilars market estimates & forecasts by Product 2019-2028 (USD Billion)
TABLE 4. Global Biosimilars market estimates & forecasts by Indication 2019-2028 (USD Billion)
TABLE 5. Global Biosimilars market by segment, estimates & forecasts, 2019-2028 (USD Billion)
TABLE 6. Global Biosimilars market by region, estimates & forecasts, 2019-2028 (USD Billion)
TABLE 7. Global Biosimilars market by segment, estimates & forecasts, 2019-2028 (USD Billion)
TABLE 8. Global Biosimilars market by region, estimates & forecasts, 2019-2028 (USD Billion)
TABLE 9. Global Biosimilars market by segment, estimates & forecasts, 2019-2028 (USD Billion)
TABLE 10. Global Biosimilars market by region, estimates & forecasts, 2019-2028 (USD Billion)
TABLE 11. Global Biosimilars market by segment, estimates & forecasts, 2019-2028 (USD Billion)
TABLE 12. Global Biosimilars market by region, estimates & forecasts, 2019-2028 (USD Billion)
TABLE 13. Global Biosimilars market by segment, estimates & forecasts, 2019-2028 (USD Billion)
TABLE 14. Global Biosimilars market by region, estimates & forecasts, 2019-2028 (USD Billion)
TABLE 15. U.S. Biosimilars market estimates & forecasts, 2019-2028 (USD Billion)
TABLE 16. U.S. Biosimilars market estimates & forecasts by segment 2019-2028 (USD Billion)
TABLE 17. U.S. Biosimilars market estimates & forecasts by segment 2019-2028 (USD Billion)
TABLE 18. Canada Biosimilars market estimates & forecasts, 2019-2028 (USD Billion)
TABLE 19. Canada Biosimilars market estimates & forecasts by segment 2019-2028 (USD Billion)
TABLE 20. Canada Biosimilars market estimates & forecasts by segment 2019-2028 (USD Billion)
TABLE 21. UK Biosimilars market estimates & forecasts, 2019-2028 (USD Billion)
TABLE 22. UK Biosimilars market estimates & forecasts by segment 2019-2028 (USD Billion)
TABLE 23. UK Biosimilars market estimates & forecasts by segment 2019-2028 (USD Billion)
TABLE 24. Germany Biosimilars market estimates & forecasts, 2019-2028 (USD Billion)
TABLE 25. Germany Biosimilars market estimates & forecasts by segment 2019-2028 (USD Billion)
TABLE 26. Germany Biosimilars market estimates & forecasts by segment 2019-2028 (USD Billion)
TABLE 27. RoE Biosimilars market estimates & forecasts, 2019-2028 (USD Billion)
TABLE 28. RoE Biosimilars market estimates & forecasts by segment 2019-2028 (USD Billion)
TABLE 29. RoE Biosimilars market estimates & forecasts by segment 2019-2028 (USD Billion)
TABLE 30. China Biosimilars market estimates & forecasts, 2019-2028 (USD Billion)
TABLE 31. China Biosimilars market estimates & forecasts by segment 2019-2028 (USD Billion)
TABLE 32. China Biosimilars market estimates & forecasts by segment 2019-2028 (USD Billion)
TABLE 33. India Biosimilars market estimates & forecasts, 2019-2028 (USD Billion)
TABLE 34. India Biosimilars market estimates & forecasts by segment 2019-2028 (USD Billion)
TABLE 35. India Biosimilars market estimates & forecasts by segment 2019-2028 (USD Billion)
TABLE 36. Japan Biosimilars market estimates & forecasts, 2019-2028 (USD Billion)
TABLE 37. Japan Biosimilars market estimates & forecasts by segment 2019-2028 (USD Billion)
TABLE 38. Japan Biosimilars market estimates & forecasts by segment 2019-2028 (USD Billion)
TABLE 39. RoAPAC Biosimilars market estimates & forecasts, 2019-2028 (USD Billion)
TABLE 40. RoAPAC Biosimilars market estimates & forecasts by segment 2019-2028 (USD Billion)
TABLE 41. RoAPAC Biosimilars market estimates & forecasts by segment 2019-2028 (USD Billion)
TABLE 42. Brazil Biosimilars market estimates & forecasts, 2019-2028 (USD Billion)
TABLE 43. Brazil Biosimilars market estimates & forecasts by segment 2019-2028 (USD Billion)
TABLE 44. Brazil Biosimilars market estimates & forecasts by segment 2019-2028 (USD Billion)
TABLE 45. Mexico Biosimilars market estimates & forecasts, 2019-2028 (USD Billion)
TABLE 46. Mexico Biosimilars market estimates & forecasts by segment 2019-2028 (USD Billion)
TABLE 47. Mexico Biosimilars market estimates & forecasts by segment 2019-2028 (USD Billion)
TABLE 48. RoLA Biosimilars market estimates & forecasts, 2019-2028 (USD Billion)
TABLE 49. RoLA Biosimilars market estimates & forecasts by segment 2019-2028 (USD Billion)
TABLE 50. RoLA Biosimilars market estimates & forecasts by segment 2019-2028 (USD Billion)
TABLE 51. Row Biosimilars market estimates & forecasts, 2019-2028 (USD Billion)
TABLE 52. Row Biosimilars market estimates & forecasts by segment 2019-2028 (USD Billion)
TABLE 53. Row Biosimilars market estimates & forecasts by segment 2019-2028 (USD Billion)
TABLE 54. List of secondary sources, used in the study of global Biosimilars market
TABLE 55. List of primary sources, used in the study of global Biosimilars market
TABLE 56. Years considered for the study
TABLE 57. Exchange rates considered
Similar Reports
Proteins that are designed and engineered in the laboratory for pharmaceutical interventions to treat different diseases are known as protein therapeutics. The global protein therapeutics market accounted for $140,109 million in 2016, and is anticipated to rea...
- Publish Date: November 14, 2017
- $5370
Umbilical cord blood bank is storage facility that collects cord blood after the childbirth from placenta. Cord blood is rich source of stem cell used in treatment of different chronic diseases. Private and public cord blood banks are the two major types of banks that are prevalent in th...
- Publish Date: July 20, 2017
- $5370
The pharmaceutical agents that are administered to treat, diagnose, and prevent life-threatening diseases (rare diseases) are known as orphan drugs. The global orphan drugs market accounted for $106 billion in 2015, and is anticipated to reach $169 billio...
- Publish Date: April 24, 2017
- $5370
